Childhood Hereditary Spherocytosis Confirmed by Hematology Analyzer
By LabMedica International staff writers Posted on 25 Feb 2015 |
Image: The CELL-DYN Sapphire hematology analyzer (Photo courtesy of Abbott Diagnostics).
The hallmark of hereditary spherocytosis (HS) is a decreased surface area-to-volume ratio of the erythrocytes (RBC), resulting in the characteristic spherocyte form and in a blood film, spherocytes have a smaller diameter than normal RBC and are hyperchromic.
The flow cytometric eosin-5′-maleimide test (EMA) is highly sensitive and specific for HS as a confirmatory method and the utility of hyperchromic erythrocytes in HS screening and evaluation of the EMA test performed on a hematology analyzer was compared with the reference method.
Hematologists at Our Lady's Children's Hospital (Crumlin, Dublin, Ireland) analyzed blood samples from 740 pediatric patients presenting at their institution in the reticulocyte mode of the CELL-DYN Sapphire hematology analyzer (Abbott Diagnostics; Wiesbaden-Delkenheim, Germany) to obtain hyperchromic erythrocyte counts. The EMA test used as a reference for the laboratory diagnosis of HS was performed on a FACSCanto II flow cytometer (Becton Dickinson; San Jose, CA, USA).
Hyperchromic erythrocytes were the highest in patients with HS (median 11.5%; range 5.1 to 29.2%). Patients with autoimmune hemolytic disease had significantly less hyperchromic erythrocytes (median 4.9%; range 0.0 to 18.3%). Hyperchromic erythrocytes showed a high area under the receiver operating characteristic (ROC) curve of 0.972. At 4.9% cut-off, hyperchromic erythrocytes detected HS with 96.4% sensitivity and 99.1% specificity. The EMA test on CELL-DYN Sapphire correlated strongly with the reference test and had identical diagnostic power. Stability studies with blood from HS patients showed a significant decrease in hyperchromic erythrocytes after six hours of storage.
The authors concluded that measurement of hyperchromic erythrocytes is highly sensitive and specific for detecting HS and can be used for rapid and inexpensive screening. If required, the EMA test can be performed on the CELL-DYN Sapphire or a standard flow cytometer for confirmation of HS. The study was published in the February 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
Our Lady's Children's Hospital
Abbott Diagnostics
Becton Dickinson
The flow cytometric eosin-5′-maleimide test (EMA) is highly sensitive and specific for HS as a confirmatory method and the utility of hyperchromic erythrocytes in HS screening and evaluation of the EMA test performed on a hematology analyzer was compared with the reference method.
Hematologists at Our Lady's Children's Hospital (Crumlin, Dublin, Ireland) analyzed blood samples from 740 pediatric patients presenting at their institution in the reticulocyte mode of the CELL-DYN Sapphire hematology analyzer (Abbott Diagnostics; Wiesbaden-Delkenheim, Germany) to obtain hyperchromic erythrocyte counts. The EMA test used as a reference for the laboratory diagnosis of HS was performed on a FACSCanto II flow cytometer (Becton Dickinson; San Jose, CA, USA).
Hyperchromic erythrocytes were the highest in patients with HS (median 11.5%; range 5.1 to 29.2%). Patients with autoimmune hemolytic disease had significantly less hyperchromic erythrocytes (median 4.9%; range 0.0 to 18.3%). Hyperchromic erythrocytes showed a high area under the receiver operating characteristic (ROC) curve of 0.972. At 4.9% cut-off, hyperchromic erythrocytes detected HS with 96.4% sensitivity and 99.1% specificity. The EMA test on CELL-DYN Sapphire correlated strongly with the reference test and had identical diagnostic power. Stability studies with blood from HS patients showed a significant decrease in hyperchromic erythrocytes after six hours of storage.
The authors concluded that measurement of hyperchromic erythrocytes is highly sensitive and specific for detecting HS and can be used for rapid and inexpensive screening. If required, the EMA test can be performed on the CELL-DYN Sapphire or a standard flow cytometer for confirmation of HS. The study was published in the February 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
Our Lady's Children's Hospital
Abbott Diagnostics
Becton Dickinson
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data